Evidence map›Paper›PMID 31361999›Full record

ArticleJournal of neuroscience methods2019

A mouse model for chronic intermittent electronic cigarette exposure exhibits nicotine pharmacokinetics resembling human vapers.

Xuesi M Shao, Briana Lopez, David Nathan, Julian Wilson, Emmanuel Bankole, Hayk Tumoyan, Alexandra Munoz, Jorge Espinoza-Derout, Kamrul M Hasan, Scarlett Chang and 4 more

Abstract read
In one paragraph

Article in Journal of neuroscience methods, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. The respiratory epithelium in the era of vaping: insights fromEuropean respiratory review : an official journal of the European Respiratory Society · 2025
    Review
  8. Article
  9. The impact of electronic cigarettes on airway epithelial barrier integrity in preclinical mouse model.American journal of physiology. Lung cellular and molecular physiology · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xuesi M ShaoDivision of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA; David Geffen School of Medicine at University of California, Los Angeles, CA, USA. Electronic address: mshao@g.ucla.edu.
Briana LopezDivision of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA; Friends Research Institute, Cerritos, CA, USA.
David NathanDivision of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA; Friends Research Institute, Cerritos, CA, USA.
Julian WilsonDivision of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA.
Emmanuel BankoleDivision of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA.
Hayk TumoyanDivision of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA.
Alexandra MunozDivision of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA.
Jorge Espinoza-DeroutDivision of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA.
Kamrul M HasanDivision of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA.
Scarlett ChangDivision of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA.
Christina DuDivision of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA.
Amiya P Sinha-HikimDivision of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA; David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
Kabirullah LutfyDivision of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA; College of Pharmacy, Western University of Health Sciences, Pomona, CA, USA.
Theodore C FriedmanDivision of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA; David Geffen School of Medicine at University of California, Los Angeles, CA, USA; Friends Research Institute, Cerritos, CA, USA.

Funding

Sustaining Faculty Development & Community EngagementS21MD000103 · NIMHD · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI CARLISLE, DAVID M · 2001 to 2015
$73.9M
Workshop for Junior Biostatisticians in Health ResearchU54MD007598 · NIMHD · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI Piwen Wang · 2012 to 2026
$60.0M
Drew MIDARP (Infrastructure in Drug Abuse Research)R24DA017298 · NIDA · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI FRIEDMAN, THEODORE C · 2004 to 2018
$5.0M
Maternal inhaled nicotine leads to aberrant development of hypertensive phenotypeR01HL135623 · NHLBI · LOMA LINDA UNIVERSITY · PI SHAO, XUESI MAX, XIAO, DALIAO · 2017 to 2021
$2.3M
Developing an efficient E-cigarette aerosol generation and exposure system for rodent models with aerosol characteristics equivalent to those inhaled by E-cigarette usersR42DA044788 · NIDA · AUTOMATE SCIENTIFIC, INC. · PI KEWEKORDES, JOSEF, SHAO, XUESI MAX · 2019 to 2020
$884k
Developing an efficient E-cigarette aerosol generation and exposure system for rodent models with aerosol characteristics equivalent to those inhaled by E-cigarette usersR41DA044788 · NIDA · AUTOMATE SCIENTIFIC, INC. · PI KEWEKORDES, JOSEF, SHAO, XUESI MAX · 2018 to 2018
$150k
NHLBI NIH HHS R01 HL135623NIDA NIH HHS R24 DA017298NIDA NIH HHS R41 DA044788NIDA NIH HHS R42 DA044788NIMHD NIH HHS S21 MD000103NIMHD NIH HHS U54 MD007598
6 · The paper itself

Abstract

Electronic cigarettes (E-cig) use is increasing rapidly, particularly among youths. Animal models for E-cig exposure with pharmacokinetics resembling human E-cig users are lacking. We developed an E-cig aerosol exposure system for rodents and a chronic intermittent delivery method that simulates E-cig users who vape episodically during wakefulness and abstain during sleep. Mice were exposed to E-cig in a programmed schedule at very low, low, medium, or high doses defined by duration of each puff, number of puffs per delivery episode and frequency of episodes in the dark phase of a 12/12-h circadian cycle for 9 consecutive days. The plasma nicotine/cotinine levels and their time courses were determined using LC/MS-MS. We assessed the body weight, food intake and locomotor activity of Apolipoprotein E null (ApoE-/-) mice exposed to chronic intermittent E-cig aerosol. Plasma nicotine and cotinine levels were positively correlated with exposure doses. Nicotine and cotinine levels showed a circadian variation as they increased with time up to the maximum nicotine level of 21.8 ± 7.1 ng/mL during the daily intermittent E-cig exposure in the 12-h dark phase and then declined during the light phase when there was no E-cig delivery. Chronic E-cig exposure to ApoE-/- mice decreased body weight, food intake and increased locomotion. Our rodent E-cig exposure system and chronic intermittent exposure method yield clinically relevant nicotine pharmacokinetics associated with behavioral and metabolic changes. The methodologies are essential tools for in vivo studies of the health impacts of E-cig exposure on CNS, cardiovascular, pulmonary, hepatic systems, metabolism and carcinogenesis.

Indexed as

AerosolsElectronic Nicotine Delivery SystemsAnimalsApolipoproteins EBehavior, AnimalCotinineDisease Models, AnimalMaleMiceMice, Inbred C57BLMice, KnockoutNicotineNicotinic AgonistsVapingAerosolsApoe protein, mouseApolipoproteins ECotinineNicotineNicotinic AgonistsAerosolChronic intermittent exposureE-cigaretteNicotinePharmacokinetics

Identifiers

PMID31361999
PMCPMC6717674

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.